A new frontier: FDA approvals for gene therapy in sickle cell disease

Affiliations

¹ Department of Hematology, St. Jude Children's Research Hospital, Memphis, TN, USA.
² Cellular and Molecular Therapeutics Branch, National Heart, Lung, and Blood Institute and National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA. Electronic address: johntis@mail.nih.gov.

Editorial

Alexis Leonard et al. Mol Ther. 2024.

. 2024 Feb 7;32(2):264-267.

doi: 10.1016/j.ymthe.2024.01.015. Epub 2024 Jan 20.

¹ Department of Hematology, St. Jude Children's Research Hospital, Memphis, TN, USA.
² Cellular and Molecular Therapeutics Branch, National Heart, Lung, and Blood Institute and National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA. Electronic address: johntis@mail.nih.gov.

No abstract available

References

1. FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease [press Release] 2023. December 8, 2023.
1. Pauling L., Itano H.A., Singer S.J., Wells I.C. Sickle cell anemia, a molecular disease. Science. 1949;109:443. - PubMed
1. May C., Rivella S., Callegari J., Heller G., Gaensler K.M., Luzzatto L., Sadelain M. Therapeutic haemoglobin synthesis in beta-thalassaemic mice expressing lentivirus-encoded human beta-globin. Nature. 2000;406:82–86. - PubMed
1. Kanter J., Thompson A.A., Pierciey F.J., Jr., Hsieh M., Uchida N., Leboulch P., Schmidt M., Bonner M., Guo R., Miller A., et al. Lovo-cel gene therapy for sickle cell disease: Treatment process evolution and outcomes in the initial groups of the HGB-206 study. Am. J. Hematol. 2023;98:11–22. - PMC - PubMed
1. Tisdale J.F., Pierciey F.J., Kamble R., Kanter J., Krishnamurti L., Kwiatkowski J.L., Thompson A.A., Shestopalov I., Bonner M., Joseney-Antoine M., et al. Successful Plerixafor-Mediated Mobilization, Apheresis, and Lentiviral Vector Transduction of Hematopoietic Stem Cells in Patients with Severe Sickle Cell Disease. Blood. 2017;130:990.